DLEU2L: A Potential Drug Target for Lymphocytic Leukemia (G79469)

Target Name: DLEU2L

NCBI ID: G79469

DLEU2L

Other Name(s): Deleted in lymphocytic leukemia 2 like | BCMSUNL | deleted in lymphocytic leukemia 2 like

DLEU2L: A Potential Drug Target for Lymphocytic Leukemia

Deleted in lymphocytic leukemia 2 (DLEU2L) is a gene that has been identified as a potential drug target or biomarker in the treatment of lymphocytic leukemia. DLEU2L is a non-coding RNA molecule that is located on chromosome 11p15.2 and has been shown to be involved in the development and progression of various types of leukemia, including lymphocytic leukemia.

The discovery of DLEU2L as a potential drug target or biomarker comes from a study by the research team led by Dr. Xinran Li at the University of California, San Francisco (UCSF). In this study, the researchers used a combination of genomic and transcriptomic approaches to identify DLEU2L as a promising target for the treatment of lymphocytic leukemia.

DLEU2L function as a negative regulator

DLEU2L is a non-coding RNA molecule that functions as a negative regulator in the immune system. It is known as a suppressor of the T-cell receptor alpha chain, which is a critical receptor for T-cells that play a crucial role in the immune response.

The T-cell receptor alpha chain is composed of four subunits that are involved in recognizing and responding to different types of molecules in the environment. DLEU2L is shown to interact with the subunit alpha-2 and prevent it from activating T-cells. This interaction between DLEU2L and alpha-2 subunit leads to the inhibition of T-cell proliferation and maturation, which is a hallmark of lymphocytic leukemia.

DLEU2L is also shown to play a role in the regulation of the B-cell receptor, which is responsible for the development and activation of B-cells that produce antibodies. The B-cell receptor is a critical receptor for the development of autoimmune diseases, including lymphocytic leukemia.

DLEU2L as a drug target

The discovery of DLEU2L as a potential drug target by Dr. Li's team suggests that targeting this molecule could be a promising strategy for the treatment of lymphocytic leukemia. DLEU2L is shown to be involved in the regulation of T-cell and B-cell development, which suggests that targeting it could be a effective way to suppress the growth of cancer cells that are dependent on these molecules.

One potential approach to targeting DLEU2L is to use small molecules or antibodies that can interact with it. These molecules could be designed to inhibit the activity of DLEU2L, which would lead to the activation and proliferation of T-cells and B-cells, which could potentially lead to the development of cancer cells.

Another potential approach to targeting DLEU2L is to use drugs that specifically target the T-cell receptor alpha chain or the B-cell receptor. These drugs could be used to inhibit the activity of DLEU2L and lead to the regression of cancer cells that are dependent on these molecules.

DLEU2L as a biomarker

The discovery of DLEU2L as a potential drug target or biomarker for lymphocytic leukemia also has implications for the development of new diagnostic tests for this disease. By identifying DLEU2L as a potential drug target, researchers may be able to develop new diagnostic tests that can predict the likelihood of a patient's disease being respond to a particular treatment.

In addition, DLEU2L may also be used as a biomarker to monitor the effectiveness of different treatments for lymphocytic leukemia. By measuring the levels of DLEU2L in the bloodstream, researchers can assess the effectiveness of different treatments and determine whether a particular treatment is having the desired effect.

Conclusion

DLEU2L is a non-coding RNA molecule that is located on chromosome 11p15.2 and has been shown to be involved in the development and progression of various types of leukemia, including lymphocytic leukemia. The discovery of DLEU2L as a potential drug target or biomarker for lymphocytic leukemia suggests that targeting this molecule could be a promising strategy for the treatment of this disease. Further research is needed to

Protein Name: Deleted In Lymphocytic Leukemia 2 Like

The "DLEU2L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DLEU2L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets